{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:01:42Z","timestamp":1753891302250,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Lipoprotein glomerulopathy (LPG) is a rare inherited disease caused by mutations in the APOE gene, encoding apolipoprotein E (apoE). Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by overactivation of the alternative complement pathway. Here we report the case of a 21-year-old man with LPG who developed aHUS. A functional complement assay demonstrated an overactivation of the complement system. Complementary genetic analysis revealed a homozygous aHUS risk allele for complement factor-H related 1 (CFHR1), CFHR1<jats:sup>*<\/jats:sup>B. To the best of our knowledge, this is the first report of an aHUS in a patient with LPG.<\/jats:p>","DOI":"10.3389\/fmed.2021.679048","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T05:57:21Z","timestamp":1622613441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Lipoprotein Glomerulopathy Complicated by Atypical Hemolytic Uremic Syndrome"],"prefix":"10.3389","volume":"8","author":[{"given":"Lara","family":"Kollbrunner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Hirt-Minkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bresin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Neuhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Hopfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas W.","family":"Jehle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s10157-013-0887-4","article-title":"Topics in lipoprotein glomerulopathy: an overview","volume":"18","author":"Saito","year":"2014","journal-title":"Clin Exp Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1281","DOI":"10.1002\/mgg3.1281","article-title":"Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations","volume":"8","author":"Yang","year":"2020","journal-title":"Mol Genet Genomic Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/ki.2013.335","article-title":"Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation","volume":"85","author":"Hu","year":"2014","journal-title":"Kidney Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.kint.2019.10.031","article-title":"Apolipoprotein E-related glomerular disorders","volume":"97","author":"Saito","year":"2020","journal-title":"Kidney Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0272-6386(89)80134-9","article-title":"Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia","volume":"13","author":"Saito","year":"1989","journal-title":"Am J Kidney Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ekir.2018.09.020","article-title":"Unusual case of lipoprotein glomerulopathy first diagnosed in a protocol kidney allograft biopsy","volume":"4","author":"Batal","year":"2019","journal-title":"Kidney Int Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jim.2018.07.006","article-title":"Atypical hemolytic uremic syndrome: review of clinical presentation, diagnosis and management","volume":"461","author":"Sridharan","year":"2018","journal-title":"J Immunol Methods."},{"key":"B8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1182\/blood-2009-05-223834","article-title":"Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome","volume":"114","author":"Abarrategui-Garrido","year":"2009","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000045513","article-title":"Association of a novel 3-amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy","volume":"83","author":"Konishi","year":"1999","journal-title":"Nephron."},{"key":"B11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10157-010-0333-9","article-title":"Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol","volume":"14","author":"Hamatani","year":"2010","journal-title":"Clin Exp Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/rth2.12016","article-title":"Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing","volume":"1","author":"Fidalgo","year":"2017","journal-title":"Res Pract Thromb Haemost."},{"key":"B14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/children8020112","article-title":"Hemolytic uremic syndrome due to methylmalonic acidemia and homocystinuria in an infant: a case report and literature review","volume":"8","author":"Karava","year":"2021","journal-title":"Children."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa230.","article-title":"Thrombotic microangiopathy and their mimickers","author":"Palma","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1471-2369-14-53","article-title":"A case of lipoprotein glomerulopathy with thrombotic microangiopathy due to malignant hypertension","volume":"14","author":"Wu","year":"2013","journal-title":"BMC Nephrol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.4049\/jimmunol.1600053","article-title":"FHR3 blocks C3d-mediated coactivation of human B cells","volume":"197","author":"Buhlmann","year":"2016","journal-title":"J Immunol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.679048\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T05:57:23Z","timestamp":1622613443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.679048\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":20,"alternative-id":["10.3389\/fmed.2021.679048"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.679048","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"article-number":"679048"}}